FILE:ABT/ABT-8K-20020813170609.txt.gz
EVENTS:	Financial statements and exhibits	
TEXT:
ITEM: Financial statements and exhibits
ITEM: 
QuickLinks
-- Click here to rapidly navigate through this document
Item 7.    Financial Statements and Exhibits
(c)
Exhibits.
        These exhibits are furnished pursuant to Item 9 hereof and should not be deemed to be "filed" under the Securities Exchange Act of 1934.
Item 9.    Regulation FD Disclosure
        On August 13, 2002, Miles D. White, Chairman of the Board and Chief Executive Officer of Abbott Laboratories ("Abbott"), and Thomas C. Freyman, Abbott's Senior Vice President, Finance and Chief Financial Officer, each submitted to the Securities and Exchange Commission his sworn statement pursuant to Securities and Exchange Commission Order No. 4-460, and made certifications pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. The exhibits attached to this Form 8-K are hereby furnished pursuant to Item 9.
        Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
QuickLinks
Item 7. Financial Statements and Exhibits
Item 9. Regulation FD Disclosure
SIGNATURE
EXHIBIT INDEX

QuickLinks
-- Click here to rapidly navigate through this document
Exhibit 99.1
I, Miles D. White, state and attest that:
(1)
To the best of my knowledge, based upon a review of the covered reports of Abbott Laboratories, and, except as corrected or supplemented in a subsequent covered report:
 - 
no covered report contained an untrue statement of a material fact as of the end of the period covered by such report (or in the case of a report on Form 8-K or definitive proxy materials, as of the date on which it was filed); and
 - 
no covered report omitted to state a material fact necessary to make the statements in the covered report, in light of the circumstances under which they were made, not misleading as of the end of the period covered by such report (or in the case of a report on Form 8-K or definitive proxy materials, as of the date on which it was filed).
(2)
I have reviewed the contents of this statement with the Company's audit committee.
(3)
In this statement under oath, each of the following, if filed on or before the date of this statement, is a "covered report":
 - 
Report on Form 10-K for the fiscal year ended December 31, 2001 of Abbott Laboratories;
 - 
all reports on Form 10-Q, all reports on Form 8-K and all definitive proxy materials of Abbott Laboratories filed with the Commission subsequent to the filing of the Form 10-K identified above; and
 - 
any amendments to any of the foregoing.
QuickLinks
Exhibit 99.1

QuickLinks
-- Click here to rapidly navigate through this document
Exhibit 99.2
I, Thomas C. Freyman, state and attest that:
(1)
To the best of my knowledge, based upon a review of the covered reports of Abbott Laboratories, and, except as corrected or supplemented in a subsequent covered report:
 - 
no covered report contained an untrue statement of a material fact as of the end of the period covered by such report (or in the case of a report on Form 8-K or definitive proxy materials, as of the date on which it was filed); and
 - 
no covered report omitted to state a material fact necessary to make the statements in the covered report, in light of the circumstances under which they were made, not misleading as of the end of the period covered by such report (or in the case of a report on Form 8-K or definitive proxy materials, as of the date on which it was filed).
(2)
I have reviewed the contents of this statement with the Company's audit committee.
(3)
In this statement under oath, each of the following, if filed on or before the date of this statement, is a "covered report":
 - 
Report on Form 10-K for the fiscal year ended December 31, 2001 of Abbott Laboratories;
 - 
all reports on Form 10-Q, all reports on Form 8-K and all definitive proxy materials of Abbott Laboratories filed with the Commission subsequent to the filing of the Form 10-K identified above; and
 - 
any amendments to any of the foregoing.
QuickLinks
Exhibit 99.2

QuickLinks
-- Click here to rapidly navigate through this document
Exhibit 99.3
        In connection with the Quarterly Report of Abbott Laboratories (the "Company") on Form 10-Q for the period ended June 30, 2002 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Miles D. White, Chairman of the Board and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C.  1350, as adopted pursuant to  906 of the Sarbanes-Oxley Act of 2002, that:
(1)
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
/s/  
MILES D. WHITE
     Miles D. White Chairman of the Board and Chief Executive Officer August 13, 2002
QuickLinks
Exhibit 99.3

QuickLinks
-- Click here to rapidly navigate through this document
Exhibit 99.4
        In connection with the Quarterly Report of Abbott Laboratories (the "Company") on Form 10-Q for the period ended June 30, 2002 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Thomas C. Freyman, Senior Vice President, Finance and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C.  1350, as adopted pursuant to  906 of the Sarbanes-Oxley Act of 2002, that:
(1)
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
/s/  
THOMAS C. FREYMAN
      Thomas C. Freyman Senior Vice President, Finance and Chief Financial Officer August 13, 2002
QuickLinks
Exhibit 99.4


